Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 4
Submit an article Journal homepage
45
Views
2
CrossRef citations to date
0
Altmetric
Review

Novel therapies in the treatment of irritable bowel syndrome

Driss Berrada Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Dana 501, 330 Brookline Avenue, Boston, MA 02215, USA
&
Tony Lembo Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Dana 501, 330 Brookline Avenue, Boston, MA 02215, USA
Pages 635-645 | Published online: 02 Mar 2005

Bibliography

  • SAITO YA, LOCKE GR, TALLEY NJ et al.: A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am. Gastroenterol (2000) 95(10):2816–2824.
  • •Article comparing two major IBS diagnostic criteria.
  • LOCKE GR, YAWN BP, WOLLAN PC, LYDICK E: The incidence of clinically diagnosed irritable bowel syndrome in the community. Gastroenterology (1999) 116:A76.
  • CAMILLERI M, WILLIAMS DE: Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures. Pharmacoeconomics (2000) 4: 331–338
  • LEVY RL, VON KORFF M, WHITEHEAD WE et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am. Gastroenterol (2001) 96(11):3122–3129.
  • GRALNEK IM, HAYS RD, KILBOURNE A, NALIBOFF B, MAYER EA: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 119(3):654–660.
  • BERTRAM S, KURLAND M, LYDICK E, LOCKE GR 3rd, YAWN BP: The patient's perspective of irritable bowel syndrome. Fam. Pract. (2001) 50(6):521–525.
  • EVERHART JE, RENAULT PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology (1991) 100(4):998–1005.
  • YAWN BP, LOCKE GR 3rd, LYDICK E et al.: Diagnosis and care of irritable bowel syndrome in a community-based population. Am. I Manag. Care (2001) 7(6):585–592.
  • DROSSMAN DA, CAMILLERI M, MAYER EA, WHITEHEAD WE: AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 123(6):2108–2131.
  • ••Highly recommended technical review onIBS.
  • THOMPSON WG, LONGSTRETH GF, DROSSMAN DA et al.: Functional bowel disorders and functional abdominal pain. Gut (1999) 45 (Suppl 2): 1143–1147.
  • HORWITZ BJ, FISHER RS: The irritable bowel syndrome. N Engl. Med. (2001) 344(24):1846–1850.
  • COLWELL LJ, PRATHER CM, PHILLIPS SF, ZINSMEISTER AR: Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am. Gastroenterol (1998) 93(6):901–905.
  • WEEKS J: C. A. M. Complementary & alternative medicine. Mission & money in integrative medicine. Health Forum (2001) 44(1):44.
  • YAN D, SCHULTE MK, BLOOM KE, WHITE MM: Structural features of the ligand-binding domain of the serotonin 5HT3 receptor. Biol. Chem. (1999) 274(9):5537–5541.
  • FARTHING MJ: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand..I. Gastroenterol Sapp]. (1991) 188:92–100.
  • TALLEY NJ: Serotoninergic neuroenteric modulators. Lancet (2001) 358(9298):2061–2068.
  • •An excellent review on serotoninergic modulators.
  • HIGGINS GA, KILPATRICK GJ: 5-HT(3) receptor antagonists. Expert Opin. Investig. Drugs(1999) 8(12):2183–2188.
  • HUMPHREY PP, BOUNTRA C, CLAYTON N, KOZLOWSKI K: Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 2):31–38.
  • TALLEY NJ: Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol Ther. (1992) 6(3):273–289.
  • ZIGHELBOIM J, TALLEY NJ, PHILLIPS SF, HARMSEN WS, ZINSMEISTER AR: Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin Type 3 antagonism. DV. Dis. Sci. (1995) 40(4):819–827.
  • BANNER SE, SANGER GJ: Differences between 5-HT3receptor antagonists in modulation of visceral hypersensitivity. Br. Pharmacol (1995) 114(2):558–562.
  • PRIOR A, READ NW: Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol Ther. (1993) 7(2):175–180.
  • STEADMAN CJ, TALLEY NJ, PHILLIPS SF, ZINSMEISTER AR: Selective 5-hydroxytryptamine Type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin. Proc. (1992) 67(8):732–738.
  • HOUGHTON LA, FOSTER JM, WHORWELL PJ: Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol The]: (2000) 14(6):775–782.
  • DELVAUX M, LOU VEL D, MAMET JP, CAMP OS-ORIOLAR, FREXINOS J: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol Ther. (1998) 12(9):849–855.
  • BERMAN SM, CHANG L, SUYENOBU B et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology (2002) 123(4):969–977.
  • BARDHAN KD, BODEMAR G, GELDOF H et al.: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol Ther. (2000) 14(1):23–34.
  • EDWARDS EB, HEITMAN CK, HALL P et al.: A twelve-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, Phase II study to assess the clinical efficacy of alosetron (GR68755) in male subjects with irritable bowel syndrome. Am. Gativenterol (2001) 96(9):5317.
  • GUNPUT MD: Review article: clinical pharmacology of alosetron. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 2):70–76.
  • VIRAMONTES BE, CAMILLERI M, MCKINZIE S et al.: Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. Gastroenterol (2001) 96(9):2671–2676.
  • KAMM MA: Review article: the complexity of drug development for irritable bowel syndrome. Aliment. Pharmacol Ther. (2002) 16(3):343–351.
  • CAMILLERI M, NORTHCUTT AR, KONG S et al.: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355(9209):1035–1040.
  • •Multicentre study showing the efficacy of alosetron in IBS.
  • LEMBO T, WRIGHT RA, BAGBY B et al.: Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. Gastroenterol. (2001) 96(9):2662–2670.
  • JONES RH, HOLTMANN G, RODRIGO L et al.: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharmacol. The]: (1999) 13(11):1419–1427.
  • WATSON ME, LACEY L, KONG S et al: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am. Gastroenterol. (2001) 96(2):455–459.
  • JHINGRAN P, DECKER C, WATSON M, NORTHCUTT A, RICCI JF: Alosetron reduces time lost from work in women with diarrhoea-predominant irritable bowel syndrome. Clin. Drug Invest. (2001) 21(12):843–852.
  • CAMILLERI M, MAYER EA, DROSSMAN DA et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol Ther. (1999) 13(9):1149–1159.
  • FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120(2):557–560.
  • Alosetron (lotronex). Med. Lett. (5 August 2002) 44.
  • STACHER G: Cilansetron. Solvay. Carr. Opin. Investig. Drugs (2001) 2(10):1432–1436.
  • CAMILLERI M: Review article: tegaserod. Aliment. Pharmacol. The]: (2001) 15(3):277–289.
  • CALLAHAN MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol (2002) 35(1, Suppl.):S58–S67.
  • PFANNKUCHE HJ, BUHL T, GAMSE R et al.: The properties of a new prokinetically active drug SDZ HTF 919. Neurogastroenterol. Motu. (1995) 7:280.
  • PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118(3):463–468.
  • SCHIKOWSKI A, THE WISSEN M, MATHIS C, ROSS HG, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motu. (2002) 14(3):221–227.
  • COELHO AM, ROVIRA P, FIORAMONTI J, BUENO L: Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist colorectal distension in rats. Gastroenterology (2000) 118(4):A835:4393.
  • SCHIKOWSKI A, MATHIS C, THE WISSEN M, ROSS HG, PAK MA, ENCK P: Dose-dependent modulation of rectal afferent sensitivity a 5-HT4 receptor agonist. Gastroenterology (1999) 116(4):A643:G2805.
  • NOVARTIS: Zelmac (tegaserod). Advisory Committee briefing document, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2000).
  • BAKER DE: Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Rev Gastroenterol. Disord. (2001). 1(4):187–198.
  • LANGAKER KJ, MORRIS D, PRUITT R et al: The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). Digestion (1998) 59\(Suppl. 3):20.
  • MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. (2001) 15(10):1655–1666.
  • NOVICK J, MINER P, KRAUSE R et al: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. (2002) 16(11):1877–1888.
  • •A large multicentre study showing the efficacy of tegaserod in IBS.
  • LEFKOWITZ MP, RUEGG P, SHI Y et al: Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919. Gastroenterology (1999) 116:A1027.
  • BOURAS EP, CAMILLERI M, BURTON DD, MCKINZIE S: Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut (1999) 44(5):682–686.
  • EMMANUEL AV, KAMM MA, ROY AJ, ANTONELLI K: Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut (1998) 42(4):511–516.
  • BOURAS EP, CAMILLERI M, BURTON DD et al: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 120(2):354–360.
  • EMMANUEL AV, ROY AJ, NICHOLLS TJ, KAMM MA: Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment. Pharmacol. The]: (2002) 16(7):1347–1356.
  • OTTEN MH, SCHNEIDER H, WURZER H et al: doubleblind, placebo controlled evaluation of safety and efficacy of 12 week, twice daily treatment with prucalopride in patients with chronic constipation. Gastroenterology (1999) 116(4):A1055.
  • JOHANSON JR, MINER PB, PARKMAN HP et al.: Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double-blind, placebo-controlled trials. Gastroenterology (2000) 118(4):A175.
  • BONNAFOUS C, BUENO L, GRIFFIN PH et al: Influence of dexloxiglumide on visceromotor and pain response induced by rectal distension in rats. Gastroenterology (2002) 122:A527.
  • VARGA G: Dexlmdglumide Rotta Research Lab. Carr. Opin. Investig. Drugs (2002) 3:621–626.
  • MEIER R, GLACOVELLI G, D'AMATO M: Effect of the CCK-A receptor antagonist dexlmdglumide on post-prandial gallbladder emptying and colonic transit time in healthy volunteers. Gut (1997) 41.
  • D'AMATO M, WHORWELL PJ, THOMPSON DG et al: The CCK1 receptor antagonist dexlmdglumide does not increase the risk of gallstone formation. Am. Gastroentera (2001) 96(9):S316–S317.
  • LECCI A, VALENTI C, MAGGI CA: Tachykinin receptor antagonists in irritable bowel syndrome. Carr: Opin. Investig. Drugs (2002) 3(4):589–601.
  • JULIA V, MORTEAU O, BUENO L: Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology (1994) 107(1):94–102.
  • LORDAL M, NAVALESI G, THEODORSSON E, MAGGI CA, HELLSTROM PM: A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. Pharmaca (2001) 134(1):215–223.
  • GOLDSTEIN DJ, WANG O, GITTER BD, IYENGAR S: Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin. Neuropharmaca (2001) 24(1):16–22.
  • GOLDSTEIN DJ, WANG O, TODD LE et al: Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin. Pharmaca Ther. (2000) 67(4):419–426.
  • GOLDSTEIN DJ, OFFEN WW, KLEIN EG et al.: Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia (2001) 21(2):102–106.
  • A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology (1999) 52(7):1427–1433.
  • COULIE B, SZARKA LA, CAMILLERI M et al: Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology (2000) 119(1):41–50.
  • PARKMAN HP, MINER PB, RAO SSC et al: NT-3 improves functional constipation. Am. Gastroentera (2001) 96(9):5160–5161.
  • LOHOF AM, IP NY, POO MM: Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature (1993) 363(6427):350–353.
  • COULIE B, LEE JS, LYFORD G, CAMILLERI M: Recombinant human neurotrophin-3 increases noncholinergic smooth muscle contractility and decreases nonadrenergic noncholinergic (NANC) inhibition of myenteric neurons in guinea-pig colon. Gastroenterology (2000) 118:A710.
  • GILLIS RA, DIAS SOUZA J, HICKS KA et al.: Inhibitory control of proximal colonic motility by the sympathetic nervous system. Am. Physia (1987) 253(4, Pt 1):G531–G539.
  • NESS TJ, GEBHART GF: Differential effects of morphine and clonidine on visceral and cutaneous spinal nociceptive transmission in the rat.' Neurophysia (1989) 62(1):220–230.
  • BONNET F, BOICO O, ROSTAING S et al.: Postoperative analgesia with extradural clonidine. Br. Anaesth. (1989) 63(4):465–469.
  • TREMLETT MR, KELLY PJ, PARKINS J, HUGHES D, REDFERN N: Low-dose clonidine infusion during labour. Br. Anaesth. (1999) 83(2):257–261.
  • BUERKLE H, HUGE V, WOLFGART M et al.: Intra-articular clonidine analgesia after knee arthroscopy. Ear: Anaesthesia (2000) 17(5):295–299.
  • RUBINOFF MJ, PICCIONE PR, HOLT PR: Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test. Am. Gastroentera (1989) 84(4):372–374.
  • MORALI GA, BRAVERMAN DZ, LISSI J, GOLDSTEIN R, JACOBSOHN WZ: Effect of clonidine on gallbladder contraction and small bowel transit time in insulin-treated diabetics. Am. J. Gastroentera (1991) 86(8):995–999.
  • BHARUCHA AE, CAMILLERI M, ZINSMEISTER AR, HANSON RB: Adrenergic modulation of human colonic motor and sensory function. Am. Physia (1997) 273(5, Pt 1):G997–G1006.
  • MALCOLM A, CAMILLERI M, KOST L et al.: Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment. Pharmacol The]: (2000) 14(6):783–793.
  • PRIOR A, WILSON KM, WHORWELL PJ: Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment. Pharmaca The]: (1988) 2(6):535–539.
  • VIRAMONTES BE, MALCOLM A, CAMILLERI M et al: Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am. .1 Physia Gastrointest. Liver Physia (2001) 281(6):G1468–G1476.
  • DUNNE C: Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm. Bowe] Dis. (2001) 7(2):136–145.
  • HUNTER JO, MADDEN JA: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br. Nuti: (2002) 88\(Suppl. 1):67–72.
  • O'SULLIVAN GC: Probiotics. Br. I Surg. (2001) 88(2):161–162.
  • BRIGIDI P, VITALI B, SWENNEN E, BAZZOCCHI G, MATTEUZZI D: Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbia (2001) 152(8):735–741.
  • NIEDZIELIN K, KORDECKI H, BIRKENFELD B: A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Ear: Gastroentera Hepata (2001) 13(10):1143–1147.
  • O'SULLIVAN MA, O'MORAIN CA: Bacterial supplmentation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig. Liver Dis. (2000) 32(4):294–301.
  • BENSOUSSAN A, TALLEY NJ, HING M et al: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA (1998) 280(18):1585–1589.
  • AGNIHOTRI MS: Ayurved (ancient Indian system of medicine) and modern molecular medicine. Assoc. Physicians India (2000) 48(3):366–367.

Websites

  • http://www.fda.gov/ FDA Talk paper (November 28, 2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.